The Filing Desk

Phathom Pharmaceuticals vs Syndax Pharmaceuticals

Phathom Pharmaceuticals PHAT · Syndax Pharmaceuticals SNDX · Pharmaceuticals

Phathom Pharmaceuticals reported revenue of $175 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Phathom Pharmaceuticals' revenue grew 216.9% in its latest year, and Syndax Pharmaceuticals' grew 627.8%. Phathom Pharmaceuticals had an operating margin of -91.4%, against -158.4% at Syndax Pharmaceuticals. Free cash flow was −$167 million at Phathom Pharmaceuticals and −$323 million at Syndax Pharmaceuticals.

Side by side

Phathom PharmaceuticalsSyndax Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$175M$172M
Revenue growth216.9%627.8%
Revenue growth a year, last 5 years—158.3%
Gross margin87.1%—
Operating margin−91.4%−158.4%
Net margin−126.3%−165.6%
Free cash flow−$167M−$323M
Free cash flow margin−95.4%−187.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.4%1.2%
Last close$5.08$9.13
P/E at the last close——
Insider trades, last 12 months—sold $2.7 million
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Phathom PharmaceuticalsSyndax Pharmaceuticals
Operating margin
Percent of revenue
Phathom PharmaceuticalsSyndax Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Phathom PharmaceuticalsSyndax Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Phathom Pharmaceuticals and Syndax Pharmaceuticals pages.